{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:15:19Z","timestamp":1783469719760,"version":"3.55.0"},"reference-count":94,"publisher":"Bentham Science Publishers Ltd.","issue":"18","funder":[{"DOI":"10.13039\/501100013142","name":"Key Research and Development Project of Hainan Province","doi-asserted-by":"publisher","award":["ZDYF2017092"],"award-info":[{"award-number":["ZDYF2017092"]}],"id":[{"id":"10.13039\/501100013142","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573287"],"award-info":[{"award-number":["81573287"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773640"],"award-info":[{"award-number":["81773640"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2019,11,29]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Soluble Guanylate Cyclase (sGC) is the intracellular receptor of Nitric Oxide (NO). The activation\nof sGC results in the conversion of Guanosine Triphosphate (GTP) to the secondary messenger\ncyclic Guanosine Monophosphate (cGMP). cGMP modulates a series of downstream cascades through\nactivating a variety of effectors, such as Phosphodiesterase (PDE), Protein Kinase G (PKG) and Cyclic\nNucleotide-Gated Ion Channels (CNG). NO-sGC-cGMP pathway plays significant roles in various\nphysiological processes, including platelet aggregation, smooth muscle relaxation and neurotransmitter\ndelivery. With the approval of an sGC stimulator Riociguat for the treatment of Pulmonary Arterial\nHypertension (PAH), the enthusiasm in the discovery of sGC modulators continues for broad clinical\napplications. Notably, through activating the NO-sGC-cGMP pathway, sGC stimulator and activator\npotentiate for the treatment of various diseases, such as PAH, Heart Failure (HF), Diabetic Nephropathy\n(DN), Systemic Sclerosis (SS), fibrosis as well as other diseases including Sickle Cell Disease\n(SCD) and Central Nervous System (CNS) disease. Here, we review the preclinical and clinical studies\nof sGC stimulator and activator in recent years and prospect for the development of sGC modulators in\nthe near future.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557519666190730110600","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:36:07Z","timestamp":1564533367000},"page":"1544-1557","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?"],"prefix":"10.2174","volume":"19","author":[{"given":"Sijia","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianbin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zutao","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Graduate School of Science Kyoto University Kitashirakawa- Oiwakecho, Sakyo-Ku, kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoyun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1073\/pnas.84.24.9265","volume":"84","author":"Ignarro L.J.","year":"1987","unstructured":"Ignarro L.J.; Buga G.M.; Wood K.S.; Byrns R.E.; Chaudhuri G.; Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987,84(24),9265-9269","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-540-68964-5_13","volume":"199","author":"Stasch J-P.","year":"2009","unstructured":"Stasch J-P.; Hobbs A.J.; NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009,199(191),277-308","journal-title":"Handb Exp Pharmacol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/sj.bjp.0704778","volume":"136","author":"Stasch J-P.","year":"2002","unstructured":"Stasch J-P.; Schmidt P.; Alonso-Alija C.; Apeler H.; Dembowsky K.; Haerter M.; Heil M.; Minuth T.; Perzborn E.; Pleiss U.; Schramm M.; Schroeder W.; Schr\u00f6der H.; Stahl E.; Steinke W.; Wunder F.; NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 2002,136(5),773-783","journal-title":"Br J Pharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.2174\/092986708784567725","volume":"15","author":"Wang-Rosenke Y.","year":"2008","unstructured":"Wang-Rosenke Y.; Neumayer H.H.; Peters H.; NO signaling through cGMP in renal tissue fibrosis and beyond: Key pathway and novel therapeutic target. Curr Med Chem 2008,15(14),1396-1406","journal-title":"Curr Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"9442","DOI":"10.1002\/anie.201302588","volume":"52","author":"Follmann M.","year":"2013","unstructured":"Follmann M.; Griebenow N.; Hahn G.M.; Hartung I.; Mais F-Z.; Mittendorf J.; Schafer M.; Schirok H.; Stasch J-P.; Stoll F.; Straub A.; The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed 2013,52,9442-9462","journal-title":"Angew Chem Int Ed"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","volume":"122","author":"Sandner P.","year":"2017","unstructured":"Sandner P.; Stasch J-P.; Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. Respir Med 2017,122(Suppl. 1),S1-S9","journal-title":"Respir Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.2174\/0929867324666170509115433","volume":"24","author":"Hu L.","year":"2017","unstructured":"Hu L.; Wang Z.; Yi R.; Yi H.; Xiao S.; Chen Z.; Hu G.; Li Q.; Soluble guanylate cyclase: A new therapeutic target for fibrotic diseases. Curr Med Chem 2017,24(29),3203-3215","journal-title":"Curr Med Chem"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1182\/blood.V84.12.4226.bloodjournal84124226","volume":"84","author":"Ko F.N.","year":"1994","unstructured":"Ko F.N.; Wu C.C.; Kuo S.C.; Lee F.Y.; Teng C.M.; YC-1, a novel activator of platelet guanylate cyclase. Blood 1994,84(12),4226-4233","journal-title":"Blood"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.bjp.0702495","volume":"127","author":"Galle J.","year":"1999","unstructured":"Galle J.; Zabel U.; H\u00fcbner U.; Hatzelmann A.; Wagner B.; Wanner C.; Schmidt H.H.H.W.; Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 1999,127(1),195-203","journal-title":"Br J Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/apha.12210","volume":"210","author":"Tsou C-Y.","year":"2014","unstructured":"Tsou C-Y.; Chen C-Y.; Zhao J-F.; Su K-H.; Lee H-T.; Lin S-J.; Shyue S-K.; Hsiao S-H.; Lee T-S.; Activation of soluble guanylyl cyclase prevents foam cell formation and atherosclerosis. Acta Physiol (Oxf) 2014,210(4),799-810","journal-title":"Acta Physiol (Oxf)"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.12659\/MSMBR.891064","volume":"20","author":"Komsuoglu Celikyurt I.","year":"2014","unstructured":"Komsuoglu Celikyurt I.; Utkan T.; Ozer C.; Gacar N.; Aricioglu F.; Effects of YC-1 on learning and memory functions of aged rats. Med Sci Monit Basic Res 2014,20,130-137","journal-title":"Med Sci Monit Basic Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s00774-017-0866-z","volume":"36","author":"Wang J-W.","year":"2018","unstructured":"Wang J-W.; Yeh C-B.; Chou S.J.; Lu K-C.; Chu T-H.; Chen W-Y.; Chien J-L.; Yen M-H.; Chen T-H.; Shyu J-F.; YC-1 alleviates bone loss in ovariectomized rats by inhibiting bone resorption and inducing extrinsic apoptosis in osteoclasts. J Bone Miner Metab 2018,36(5),508-518","journal-title":"J Bone Miner Metab"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101602","volume":"9","author":"DeNiro M.","year":"2014","unstructured":"DeNiro M.; Al-Mohanna F.A.; Nuclear factor kappa-B signaling is integral to ocular neovascularization in ischemia-independent microenvironment. PLoS One 2014,9(7)","journal-title":"PLoS One"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1476-4598-13-7","volume":"13","author":"Kong J.","year":"2014","unstructured":"Kong J.; Kong F.; Gao J.; Zhang Q.; Dong S.; Gu F.; Ke S.; Pan B.; Shen Q.; Sun H.; Zheng L.; Sun W.; YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. Mol Cancer 2014,13,7","journal-title":"Mol Cancer"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1111\/bph.12708","volume":"171","author":"Chang L-C.","year":"2014","unstructured":"Chang L-C.; Lin H-Y.; Tsai M-T.; Chou R-H.; Lee F-Y.; Teng C-M.; Hsieh M-T.; Hung H-Y.; Huang L-J.; Yu Y-L.; Kuo S-C.; YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK. Br J Pharmacol 2014,171(17),4010-4025","journal-title":"Br J Pharmacol"},{"key":"ref=16","first-page":"2260","volume":"19","author":"Tsui L.","year":"2013","unstructured":"Tsui L.; Fong T-H.; Wang I.J.; The effect of 3-(5\u2032-hydroxymethyl-2\u2032-furyl)-1-benzylindazole (YC-1) on cell viability under hypoxia. Mol Vis 2013,19,2260-2273","journal-title":"Mol Vis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3892\/ijo.2012.1675","volume":"42","author":"Carroll C.E.","year":"2013","unstructured":"Carroll C.E.; Liang Y.; Benakanakere I.; Besch-Williford C.; Hyder S.M.; The anticancer agent YC-1 suppresses progestin-stimulated VEGF in breast cancer cells and arrests breast tumor development. Int J Oncol 2013,42(1),179-187","journal-title":"Int J Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1292\/jvms.15-0258","volume":"77","author":"Kambayashi S.","year":"2015","unstructured":"Kambayashi S.; Igase M.; Kobayashi K.; Kimura A.; Shimokawa Miyama T.; Baba K.; Noguchi S.; Mizuno T.; Okuda M.; Hypoxia inducible factor 1\u03b1 expression and effects of its inhibitors in canine lymphoma. J Vet Med Sci 2015,77(11),1405-1412","journal-title":"J Vet Med Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.celrep.2015.06.033","volume":"12","author":"Li Y.","year":"2015","unstructured":"Li Y.; Guo B.; Xie Q.; Ye D.; Zhang D.; Zhu Y.; Chen H.; Zhu B.; STIM1 Mediates Hypoxia-Driven Hepatocarcinogenesis via Interaction with HIF-1. Cell Rep 2015,12(3),388-395","journal-title":"Cell Rep"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.mce.2015.06.033","volume":"413","author":"Brownfoot F.C.","year":"2015","unstructured":"Brownfoot F.C.; Tong S.; Hannan N.J.; Hastie R.; Cannon P.; Tuohey L.; Kaitu\u2019u-Lino T.J.; YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia. Mol Cell Endocrinol 2015,413,202-208","journal-title":"Mol Cell Endocrinol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ejphar.2016.07.040","volume":"788","author":"Wang X.","year":"2016","unstructured":"Wang X.; Liu C.; Wu L.; Zhu S.; Potent ameliorating effect of Hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) antagonist YC-1 on combined allergic rhinitis and asthma syndrome (CARAS) in Rats. Eur J Pharmacol 2016,788,343-350","journal-title":"Eur J Pharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.3892\/ijo.2015.2922","volume":"46","author":"Cho I.R.","year":"2015","unstructured":"Cho I.R.; Kaowinn S.; Moon J.; Soh J.; Kang H.Y.; Jung C.R.; Oh S.; Song H.; Koh S.S.; Chung Y.H.; Oncotropic H-1 parvovirus infection degrades HIF-1\u03b1 protein in human pancreatic cancer cells independently of VHL and RACK1. Int J Oncol 2015,46(5),2076-2082","journal-title":"Int J Oncol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10147-016-1031-8","volume":"22","author":"Ikezawa Y.","year":"2017","unstructured":"Ikezawa Y.; Sakakibara-Konishi J.; Mizugaki H.; Oizumi S.; Nishimura M.; Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer. Int J Clin Oncol 2017,22(1),59-69","journal-title":"Int J Clin Oncol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"12653","DOI":"10.1038\/s41598-017-12929-9","volume":"7","author":"Wakiyama K.","year":"2017","unstructured":"Wakiyama K.; Kitajima Y.; Tanaka T.; Kaneki M.; Yanagihara K.; Aishima S.; Nakamura J.; Noshiro H.; Low-dose YC-1 combined with glucose and insulin selectively induces apoptosis in hypoxic gastric carcinoma cells by inhibiting anaerobic glycolysis. Sci Rep 2017,7(1),12653","journal-title":"Sci Rep"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fnmol.2017.00257","volume":"10","author":"Sun Y.","year":"2017","unstructured":"Sun Y.; Chen X.; Zhang X.; Shen X.; Wang M.; Wang X.; Liu W-C.; Liu C-F.; Liu J.; Liu W.; Jin X.; \u03b22-Adrenergic Receptor-Mediated HIF-1\u03b1 upregulation mediates blood brain barrier damage in acute cerebral ischemia. Front Mol Neurosci 2017,10,257","journal-title":"Front Mol Neurosci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fncel.2018.00288","volume":"12","author":"Shen Y.","year":"2018","unstructured":"Shen Y.; Gu J.; Liu Z.; Xu C.; Qian S.; Zhang X.; Zhou B.; Guan Q.; Sun Y.; Wang Y.; Jin X.; Inhibition of HIF-1\u03b1 reduced blood brain barrier damage by regulating MMP-2 and VEGF during acute cerebral ischemia. Front Cell Neurosci 2018,12,288","journal-title":"Front Cell Neurosci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.biopha.2017.04.103","volume":"91","author":"Sun H-D.","year":"2017","unstructured":"Sun H-D.; Liu Y-J.; Chen J.; Chen M-Y.; Ouyang B.; Guan X-D.; The pivotal role of HIF-1\u03b1 in lung inflammatory injury induced by septic mesenteric lymph. Biomed Pharmacother 2017,91,476-484","journal-title":"Biomed Pharmacother"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1051\/bmdcn\/2017070205","volume":"7","author":"Lee M-R.","year":"2017","unstructured":"Lee M-R.; Lin C.; Lu C-C.; Kuo S-C.; Tsao J-W.; Juan Y-N.; Chiu H-Y.; Lee F-Y.; Yang J-S.; Tsai F-J.; YC-1 induces G\/G phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells. Biomedicine (Taipei) 2017,7(2),12","journal-title":"Biomedicine (Taipei)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.3892\/ol.2018.9266","volume":"16","author":"Ding X.","year":"2018","unstructured":"Ding X.; Kong J.; Xu W.; Dong S.; Du Y.; Yao C.; Gao J.; Ke S.; Wang S.; Sun W.; ATPase inhibitory factor 1 inhibition improves the antitumor of YC-1 against hepatocellular carcinoma. Oncol Lett 2018,16(4),5230-5236","journal-title":"Oncol Lett"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.7150\/jca.24201","volume":"9","author":"Zhao Z.","year":"2018","unstructured":"Zhao Z.; Xia G.; Li N.; Su R.; Chen X.; Zhong L.; Autophagy inhibition promotes bevacizumab-induced apoptosis and proliferation inhibition in colorectal cancer cells. J Cancer 2018,9(18),3407-3416","journal-title":"J Cancer"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"6490","DOI":"10.3892\/mmr.2018.8660","volume":"17","author":"Tai S.H.","year":"2018","unstructured":"Tai S.H.; Lee W.T.; Lee A.C.; Lin Y.W.; Hung H.Y.; Huang S.Y.; Wu T.S.; Lee E.J.; Therapeutic window for YC-1 following glutamate-induced neuronal damage and transient focal cerebral ischemia. Mol Med Rep 2018,17(5),6490-6496","journal-title":"Mol Med Rep"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1080\/02713683.2018.1426102","volume":"43","author":"Yan Z.","year":"2018","unstructured":"Yan Z.; An J.; Shang Q.; Zhou N.; Ma J.; YC-1 Inhibits VEGF and inflammatory mediators expression on experimental central retinal vein occlusion in rhesus monkey. Curr Eye Res 2018,43(4),526-533","journal-title":"Curr Eye Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0960-894X(01)00073-7","volume":"11","author":"Straub A.","year":"2001","unstructured":"Straub A.; Stasch J-P.; Alonso-Alija C.; Benet-Buchholz J.; Ducke B.; Feurer A.; F\u00fcrstner C.; NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 2001,11(6),781-784","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/cmdc.200900014","volume":"4","author":"Mittendorf J.","year":"2009","unstructured":"Mittendorf J.; Weigand S.; Alonso-Alija C.; Bischoff E.; Feurer A.; Gerisch M.; Kern A.; Knorr A.; Lang D.; Muenter K.; Radtke M.; Schirok H.; Schlemmer K-H.; Stahl E.; Straub A.; Wunder F.; Stasch J-P.; Discovery of riociguat (BAY 63-2521): A potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009,4(5),853-865","journal-title":"ChemMedChem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1476-5381.2012.02012.x","volume":"167","author":"Chan M.V.","year":"2012","unstructured":"Chan M.V.; Bubb K.J.; Noyce A.; Villar I.C.; Duchene J.; Hobbs A.J.; Scotland R.S.; Ahluwalia A.; Distinct endothelial pathways underlie sexual dimorphism in vascular auto-regulation. Br J Pharmacol 2012,167(4),805-817","journal-title":"Br J Pharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/annrheumdis-2011-200862","volume":"71","author":"Beyer C.","year":"2012","unstructured":"Beyer C.; Reich N.; Schindler S.C.; Akhmetshina A.; Dees C.; Tomcik M.; Hirth-Dietrich C.; von Degenfeld G.; Sandner P.; Distler O.; Schett G.; Distler J.H.; Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012,71(6),1019-1026","journal-title":"Ann Rheum Dis"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141477","volume":"10","author":"Sandner P.","year":"2015","unstructured":"Sandner P.; Tinel H.; Affaitati G.; Costantini R.; Giamberardino M.A.; Effects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral Calculosis. PLoS One 2015,10(10)","journal-title":"PLoS One"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190628","volume":"13","author":"Paul T.","year":"2018","unstructured":"Paul T.; Salazar-Degracia A.; Peinado V.I.; Tura-Ceide O.; Blanco I.; Barreiro E.; Barber\u00e0 J.A.; Soluble guanylate cyclase stimulation reduces oxidative stress in experimental Chronic Obstructive Pulmonary Disease. PLoS One 2018,13(1)","journal-title":"PLoS One"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1021\/jm001034k","volume":"44","author":"Selwood D.L.","year":"2001","unstructured":"Selwood D.L.; Brummell D.G.; Budworth J.; Burtin G.E.; Campbell R.O.; Chana S.S.; Charles I.G.; Fernandez P.A.; Glen R.C.; Goggin M.C.; Hobbs A.J.; Kling M.R.; Liu Q.; Madge D.J.; Meillerais S.; Powell K.L.; Reynolds K.; Spacey G.D.; Stables J.N.; Tatlock M.A.; Wheeler K.A.; Wishart G.; Woo C-K.; Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J Med Chem 2001,44(1),78-93","journal-title":"J Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1124\/jpet.113.205484","volume":"346","author":"Kotzki S.","year":"2013","unstructured":"Kotzki S.; Roustit M.; Arnaud C.; Boutonnat J.; Blaise S.; Godin-Ribuot D.; Cracowski J-L.; Anodal iontophoresis of a soluble guanylate cyclase stimulator induces a sustained increase in skin blood flow in rats. J Pharmacol Exp Ther 2013,346(3),424-431","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/sj.bjp.0704484","volume":"135","author":"Stasch J.P.","year":"2002","unstructured":"Stasch J.P.; Alonso-Alija C.; Apeler H.; Dembowsky K.; Feurer A.; Minuth T.; Perzborn E.; Schramm M.; Straub A.; Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 2002,135(2),333-343","journal-title":"Br J Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1097\/HJH.0000000000000648","volume":"33","author":"Stancu B.","year":"2015","unstructured":"Stancu B.; Kr\u00e4mer S.; Loof T.; Mika A.; Amann K.; Neumayer H-H.; Peters H.; Soluble guanylate cyclase stimulator BAY 41-8543 and female sex ameliorate uremic aortic remodeling in a rat model of mild uremia. J Hypertens 2015,33(9),1907-1920","journal-title":"J Hypertens"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/2211-5463.12202","volume":"7","author":"Schinner E.","year":"2017","unstructured":"Schinner E.; Wetzl V.; Schramm A.; Kees F.; Sandner P.; Stasch J-P.; Hofmann F.; Schlossmann J.; Inhibition of the TGF\u03b2 signalling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis. FEBS Open Bio 2017,7(4),550-561","journal-title":"FEBS Open Bio"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0024-3205(02)02361-5","volume":"72","author":"Miller L.N.","year":"2003","unstructured":"Miller L.N.; Nakane M.; Hsieh G.C.; Chang R.; Kolasa T.; Moreland R.B.; Brioni J.D.; A-350619: A novel activator of soluble guanylyl cyclase. Life Sci 2003,72(9),1015-1025","journal-title":"Life Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.neuropharm.2015.08.004","volume":"99","author":"Pablos P.","year":"2015","unstructured":"Pablos P.; Mendiguren A.; Pineda J.; Contribution of nitric oxide-dependent guanylate cyclase and reactive oxygen species signaling pathways to desensitization of \u03bc-opioid receptors in the rat locus coeruleus. Neuropharmacology 2015,99,422-431","journal-title":"Neuropharmacology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"29613","DOI":"10.18632\/oncotarget.16769","volume":"8","author":"Amirjanians M.","year":"2017","unstructured":"Amirjanians M.; Egemnazarov B.; Sydykov A.; Kojonazarov B.; Brandes R.; Luitel H.; Pradhan K.; Stasch J-P.; Redlich G.; Weissmann N.; Grimminger F.; Seeger W.; Ghofrani H.; Schermuly R.; Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. Oncotarget 2017,8(18),29613-29624","journal-title":"Oncotarget"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-3-662-45805-1_12","volume":"218","author":"Stasch J.P.","year":"2013","unstructured":"Stasch J.P.; Evgenov O.V.; Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013,218,279-313","journal-title":"Handb Exp Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"Ghofrani H.A.","year":"2013","unstructured":"Ghofrani H.A.; D\u2019Armini A.M.; Grimminger F.; Hoeper M.M.; Jansa P.; Kim N.H.; Mayer E.; Simonneau G.; Wilkins M.R.; Fritsch A.; Neuser D.; Weimann G.; Wang C.; Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013,369(4),319-329","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"Ghofrani H-A.","year":"2013","unstructured":"Ghofrani H-A.; Gali\u00e8 N.; Grimminger F.; Gr\u00fcnig E.; Humbert M.; Jing Z-C.; Keogh A.M.; Langleben D.; Kilama M.O.; Fritsch A.; Neuser D.; Rubin L.J.; Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013,369(4),330-340","journal-title":"N Engl J Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1183\/09031936.00087114","volume":"45","author":"Simonneau G.","year":"2015","unstructured":"Simonneau G.; D\u2019Armini A.M.; Ghofrani H-A.; Grimminger F.; Hoeper M.M.; Jansa P.; Kim N.H.; Wang C.; Wilkins M.R.; Fritsch A.; Davie N.; Colorado P.; Mayer E.; Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015,45(5),1293-1302","journal-title":"Eur Respir J"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.rmed.2017.05.008","volume":"128","author":"Halank M.","year":"2017","unstructured":"Halank M.; Hoeper M.M.; Ghofrani H-A.; Meyer F.J.; St\u00e4hler G.; Behr J.; Ewert R.; Fletcher M.; Colorado P.; Nikkho S.; Grimminger F.; Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. Respir Med 2017,128,50-56","journal-title":"Respir Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/DDDT.S117277","volume":"11","author":"Lian T-Y.","year":"2017","unstructured":"Lian T-Y.; Jiang X.; Jing Z-C.; Riociguat: A soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Des Devel Ther 2017,11,1195-1207","journal-title":"Drug Des Devel Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/annrheumdis-2015-209087","volume":"76","author":"Humbert M.","year":"2017","unstructured":"Humbert M.; Coghlan J.G.; Ghofrani H-A.; Grimminger F.; He J-G.; Riemekasten G.; Vizza C.D.; Boeckenhoff A.; Meier C.; de Oliveira Pena J.; Denton C.P.; Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017,76(2),422-426","journal-title":"Ann Rheum Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1136\/heartjnl-2015-307832","volume":"101","year":"2015","unstructured":"Rosenkranz; S.; Ghofrani, H.-A.; Beghetti, M.; Ivy, D.; Frey, R.; Fritsch, A.; Weimann, G.; Saleh, S.; Apitz, C. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart 2015,101,1792-1799","journal-title":"Heart"},{"key":"ref=55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191239","volume":"13","author":"Chamorro V.","year":"2018","unstructured":"Chamorro V.; Morales-Cano D.; Milara J.; Barreira B.; Moreno L.; Callejo M.; Mondejar-Parre\u00f1o G.; Esquivel-Ruiz S.; Cortijo J.; Cogolludo \u00c1.; Barber\u00e1 J.A.; Perez-Vizcaino F.; Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation\/perfusion matching. PLoS One 2018,13(1)","journal-title":"PLoS One"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","volume":"28","author":"Sharkovska Y.","year":"2010","unstructured":"Sharkovska Y.; Kalk P.; Lawrenz B.; Godes M.; Hoffmann L.S.; Wellkisch K.; Geschka S.; Relle K.; Hocher B.; Stasch J.P.; Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens 2010,28(8),1666-1675","journal-title":"J Hypertens"},{"key":"ref=57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021853","volume":"6","author":"Geschka S.","year":"2011","unstructured":"Geschka S.; Kretschmer A.; Sharkovska Y.; Evgenov O.V.; Lawrenz B.; Hucke A.; Hocher B.; Stasch J.P.; Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One 2011,6(7)","journal-title":"PLoS One"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1136\/annrheumdis-2014-206809","volume":"74","author":"Dees C.","year":"2015","unstructured":"Dees C.; Beyer C.; Distler A.; Soare A.; Zhang Y.; Palumbo-Zerr K.; Distler O.; Schett G.; Sandner P.; Distler J.H.; Distler J.H.W.; Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. Ann Rheum Dis 2015,74(8),1621-1625","journal-title":"Ann Rheum Dis"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"9372","DOI":"10.1038\/s41598-018-27656-y","volume":"8","author":"Schwabl P.","year":"2018","unstructured":"Schwabl P.; Brusilovskaya K.; Supper P.; Bauer D.; K\u00f6nigshofer P.; Riedl F.; Hayden H.; Fuchs C.D.; Stift J.; Oberhuber G.; Aschauer S.; Bonderman D.; Gnad T.; Pfeifer A.; Uschner F.E.; Trebicka J.; Rohr-Udilova N.; Podesser B.K.; Peck-Radosavljevic M.; Trauner M.; Reiberger T.; The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Sci Rep 2018,8(1),9372","journal-title":"Sci Rep"},{"key":"ref=60","first-page":"1","author":"Rai N.","year":"2018","unstructured":"Rai N.; Veeroju S.; Schymura Y.; Janssen W.; Wietelmann A.; Kojonazarov B.; Weissmann N.; Stasch J-P.; Ghofrani W.; Schermuly R.T.; Novoyatleva T.; Seeger W.; Effect of riociguat and sildenafil on right heart remodeling and function in pressure overload induced model of pulmonary arterial banding. BioMed Res Int 2018,1-9","journal-title":"BioMed Res Int"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fphar.2012.00128","volume":"3","author":"Costell M.H.","year":"2012","unstructured":"Costell M.H.; Ancellin N.; Bernard R.E.; Zhao S.; Upson J.J.; Morgan L.A.; Maniscalco K.; Olzinski A.R.; Ballard V.L.T.; Herry K.; Grondin P.; Dodic N.; Mirguet O.; Bouillot A.; Gellibert F.; Coatney R.W.; Lepore J.J.; Jucker B.M.; Jolivette L.J.; Willette R.N.; Schnackenberg C.G.; Behm D.J.; Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front Pharmacol 2012,3,128","journal-title":"Front Pharmacol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","volume":"21","author":"Stasch J-P.","year":"2015","unstructured":"Stasch J-P.; Schlossmann J.; Hocher B.; Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr Opin Pharmacol 2015,21,95-104","journal-title":"Curr Opin Pharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1021\/acsmedchemlett.5b00479","volume":"7","author":"Nakai T.","year":"2016","unstructured":"Nakai T.; Perl N.R.; Barden T.C.; Carvalho A.; Fretzen A.; Germano P.; Im, G.Y.; Jin, H.; Kim, C.; Lee, T.W.; Long, K.; Moore, J.; Rohde, J.M.; Sarno, R.; Segal, C.; Solberg, E.O.; Tobin, J.; Zimmer, D.P.; Currie, M.G. Discovery of IWP-051, a Novel orally bioavailable sGC stimulator with once-daily dosing potential in humans. ACS Med Chem Lett 2016,7(5),465-469","journal-title":"ACS Med Chem Lett"},{"key":"ref=64","first-page":"A3906","volume":"193","author":"Zimmer D.P.","year":"2016","unstructured":"Zimmer D.P.; Cole B.K.; Ge P.; Tang K.; Miline G.; Simmers M.; Feaver R.; Collado M.S.; Hoang S.; Lawson M.; Macky A.; Manka D.; Blackman B.R.; Ribadeneira M.; Inhibition of fibrotic and hypoxia gene response in a pulmonary vascular surrogate system with a small molecule stimulator of soluble guanylate cyclase. Am J Respir Crit Care Med 2016,193,A3906","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1167\/iovs.15-18958","volume":"57","author":"Ge P.","year":"2016","unstructured":"Ge P.; Navarro I.D.; Kessler M.M.; Bernier S.G.; Perl N.R.; Sarno R.; Masferrer J.; Hannig G.; Stamer W.D.; The soluble guanylate cyclase stimulator IWP-953 increases conventional outflow facility in mouse eyes. Invest Ophthalmol Vis Sci 2016,57(3),1317-1326","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","volume":"60","author":"Follmann M.","year":"2017","unstructured":"Follmann M.; Ackerstaff J.; Redlich G.; Wunder F.; Lang D.; Kern A.; Fey P.; Griebenow N.; Kroh W.; Becker-Pelster E-M.; Kretschmer A.; Geiss V.; Li V.; Straub A.; Mittendorf J.; Jautelat R.; Schirok H.; Schlemmer K-H.; Lustig K.; Gerisch M.; Knorr A.; Tinel H.; Mondritzki T.; Tr\u00fcbel H.; Sandner P.; Stasch J-P.; Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem 2017,60(12),5146-5161","journal-title":"J Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/ejhf.135","volume":"16","author":"Pieske B.","year":"2014","unstructured":"Pieske B.; Butler J.; Filippatos G.; Lam C.; Maggioni A.P.; Ponikowski P.; Shah S.; Solomon S.; Kraigher-Krainer E.; Samano E.T.; Scalise A.V.; M\u00fcller K.; Roessig L.; Gheorghiade M.; Rationale and design of the soluble guanylate Cyclase stimulatoR in heart failure Studies (SOCRATES). Eur J Heart Fail 2014,16(9),1026-1038","journal-title":"Eur J Heart Fail"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"Gheorghiade M.","year":"2015","unstructured":"Gheorghiade M.; Greene S.J.; Butler J.; Filippatos G.; Lam C.S.; Maggioni A.P.; Ponikowski P.; Shah S.J.; Solomon S.D.; Kraigher-Krainer E.; Samano E.T.; M\u00fcller K.; Roessig L.; Pieske B.; Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA 2015,314(21),2251-2262","journal-title":"JAMA"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ejhf.800","volume":"19","author":"Filippatos G.","year":"2017","unstructured":"Filippatos G.; Maggioni A.P.; Lam C.S.P.; Pieske-Kraigher E.; Butler J.; Spertus J.; Ponikowski P.; Shah S.J.; Solomon S.D.; Scalise A-V.; Mueller K.; Roessig L.; Bamber L.; Gheorghiade M.; Pieske B.; Patient-reported outcomes in the Soluble guanylate Cyclase stimulator in heart failure patients with preserved ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail 2017,19(6),782-791","journal-title":"Eur J Heart Fail"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","volume":"6","author":"Armstrong P.W.","year":"2018","unstructured":"Armstrong P.W.; Roessig L.; Patel M.J.; Anstrom K.J.; Butler J.; Voors A.A.; Lam C.S.P.; Ponikowski P.; Temple T.; Pieske B.; Ezekowitz J.; Hernandez A.F.; Koglin J.; O\u2019Connor C.M.A.; A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: The VICTORIA Trial. JACC Heart Fail 2018,6(2),96-104","journal-title":"JACC Heart Fail"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.niox.2018.05.009","volume":"78","author":"Buys E.S.","year":"2018","unstructured":"Buys E.S.; Zimmer D.P.; Chickering J.; Graul R.; Chien Y.T.; Profy A.; Hadcock J.R.; Masferrer J.L.; Milne G.T.; Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. Nitric Oxide 2018,78,72-80","journal-title":"Nitric Oxide"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1124\/jpet.117.247429","volume":"365","author":"Tobin J.V.","year":"2018","unstructured":"Tobin J.V.; Zimmer D.P.; Shea C.; Germano P.; Bernier S.G.; Liu G.; Long K.; Miyashiro J.; Ranganath S.; Jacobson S.; Tang K.; Im, G.J.; Sheppeck, J., II; Moore, J.D.; Sykes, K.; Wakefield, J.; Sarno, R.; Banijamali, A.R.; Profy, A.T.; Milne, G.T.; Currie, M.G.; Masferrer, J.L. Pharmacological characterization of Iw-1973, a novel soluble guanylate cyclase stimulator with extensive tissue distribution, anti-hypertensive, anti-inflammatory, and anti-fibrotic effects in preclinical models of disease. J Pharmacol Exp Ther 2018,365(3),664-675","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"A86","DOI":"10.1186\/2050-6511-16-S1-A86","volume":"16","author":"Shea C.","year":"2015","unstructured":"Shea C.; Ranganath S.; Liu G.; Wachtel D.; Germano P.; Tobin J.; Zhang P.; Rivers S.; Im, G.-Y. J.; Sheppeck II, J.; Masferrer, J. IWP-121: a novel sGC stimulator that reduces blood pressure and exhibits anti-fibrotic and anti-inflammatory activities in the Dahl Salt-Sensitive rat model. BMC Pharmacol Toxicol 2015,16(S1),A86","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"A54","DOI":"10.1186\/2050-6511-16-S1-A54","volume":"16","author":"Germano P.","year":"2015","unstructured":"Germano P.; Tobin J.; Jefferson R.; Shea C.; Smith A.; Im, G.-Y. J.; Sheppeck II, J.; Wakefield, J.; Sykes, K.; Ribadeneira, M.; Rivers, S.; Masferrer, J. Concomitant administration of sGC stimulators with common classes of anti-hypertensive agents results in increased efficacy in spontaneously hypertensive rats. BMC Pharmacol Toxicol 2015,16(S1),A54","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/bph.14137","volume":"175","author":"Flores-Costa R.","year":"2018","unstructured":"Flores-Costa R.; Alcaraz-Quiles J.; Titos E.; L\u00f3pez-Vicario C.; Casulleras M.; Duran-G\u00fcell M.; Rius B.; Diaz A.; Hall K.; Shea C.; Sarno R.; Currie M.; Masferrer J.L.; Cl\u00e0ria J.; The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis. Br J Pharmacol 2018,175(6),953-967","journal-title":"Br J Pharmacol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/ijms19061712","volume":"19","author":"Krishnan S.M.","year":"2018","unstructured":"Krishnan S.M.; Kraehling J.R.; Eitner F.; B\u00e9nardeau A.; Sandner P.; The Impact of the Nitric Oxide (NO)\/Soluble Guanylyl Cyclase (sGC) signaling cascade on kidney health and disease: A preclinical perspective. Int J Mol Sci 2018,19(6),1712","journal-title":"Int J Mol Sci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ajhg.2014.01.018","volume":"94","author":"Herv\u00e9 D.","year":"2014","unstructured":"Herv\u00e9 D.; Philippi A.; Belbouab R.; Zerah M.; Chabrier S.; Collardeau-Frachon S.; Bergametti F.; Essongue A.; Berrou E.; Krivosic V.; Sainte-Rose C.; Houdart E.; Adam F.; Billiemaz K.; Lebret M.; Roman S.; Passemard S.; Boulday G.; Delaforge A.; Guey S.; Dray X.; Chabriat H.; Brouckaert P.; Bryckaert M.; Tournier-Lasserve E.; Loss of \u03b11\u03b21 soluble guanylate cyclase, the major nitric oxide receptor, leads to moyamoya and achalasia. Am J Hum Genet 2014,94(3),385-394","journal-title":"Am J Hum Genet"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1038\/jp.2016.47","volume":"36","author":"Aschner J.L.","year":"2016","unstructured":"Aschner J.L.; Gien J.; Ambalavanan N.; Kinsella J.P.; Konduri G.G.; Lakshminrusimha S.; Saugstad O.D.; Steinhorn R.H.; Challenges, priorities and novel therapies for hypoxemic respiratory failure and pulmonary hypertension in the neonate. J Perinatol 2016,36(Suppl. 2),S32-S36","journal-title":"J Perinatol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cpt.10","volume":"97","author":"Dasgupta A.","year":"2015","unstructured":"Dasgupta A.; Bowman L.; D\u2019Arsigny C.L.; Archer S.L.; Soluble guanylate cyclase: A new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Clin Pharmacol Ther 2015,97(1),88-102","journal-title":"Clin Pharmacol Ther"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1161\/CIRCULATIONAHA.117.028723","volume":"136","author":"Frankenreiter S.","year":"2017","unstructured":"Frankenreiter S.; Bednarczyk P.; Kniess A.; Bork N.I.; Straubinger J.; Koprowski P.; Wrzosek A.; Mohr E.; Logan A.; Murphy M.P.; Gawaz M.; Krieg T.; Szewczyk A.; Nikolaev V.O.; Ruth P.; Lukowski R.; cGMP-elevating compounds and ischemic conditioning provide cardioprotection against ischemia and reperfusion injury via cardiomyocyte-specific BK channels. Circulation 2017,136(24),2337-2355","journal-title":"Circulation"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","volume":"34","author":"Erdmann E.","year":"2013","unstructured":"Erdmann E.; Semigran M.J.; Nieminen M.S.; Gheorghiade M.; Agrawal R.; Mitrovic V.; Mebazaa A.; Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 2013,34(1),57-67","journal-title":"Eur Heart J"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12933-015-0309-x","volume":"14","author":"M\u00e1ty\u00e1s C.","year":"2015","unstructured":"M\u00e1ty\u00e1s C.; N\u00e9meth B.T.; Ol\u00e1h A.; Hidi L.; Birtalan E.; Kellermayer D.; Ruppert M.; Korkmaz-Ic\u00f6z S.; K\u00f6k\u00e9ny G.; Horv\u00e1th E.M.; Szab\u00f3 G.; Merkely B.; Radovits T.; The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus. Cardiovasc Diabetol 2015,14,145","journal-title":"Cardiovasc Diabetol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1165\/rcmb.2014-0092OC","volume":"52","author":"Glynos C.","year":"2015","unstructured":"Glynos C.; Toumpanakis D.; Loverdos K.; Karavana V.; Zhou Z.; Magkou C.; Dettoraki M.; Perlikos F.; Pavlidou A.; Kotsikoris V.; Topouzis S.; Theocharis S.E.; Brouckaert P.; Giannis A.; Papapetropoulos A.; Vassilakopoulos T.; Guanylyl cyclase activation reverses resistive breathing-induced lung injury and inflammation. Am J Respir Cell Mol Biol 2015,52(6),762-771","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1164\/rccm.201210-1884OC","volume":"188","author":"Glynos C.","year":"2013","unstructured":"Glynos C.; Dupont L.L.; Vassilakopoulos T.; Papapetropoulos A.; Brouckaert P.; Giannis A.; Joos G.F.; Bracke K.R.; Brusselle G.G.; The role of soluble guanylyl cyclase in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013,188(7),789-799","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"8482","DOI":"10.1038\/ncomms9482","volume":"6","author":"Thoonen R.","year":"2015","unstructured":"Thoonen R.; Cauwels A.; Decaluwe K.; Geschka S.; Tainsh R.E.; Delanghe J.; Hochepied T.; De Cauwer L.; Rogge E.; Voet S.; Sips P.; Karas R.H.; Bloch K.D.; Vuylsteke M.; Stasch J.P.; Van de Voorde J.; Buys E.S.; Brouckaert P.; Cardiovascular and pharmacological implications of haem-deficient NO-unresponsive soluble guanylate cyclase knock-in mice. Nat Commun 2015,6,8482","journal-title":"Nat Commun"},{"key":"ref=86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145048","volume":"10","author":"Hoffmann L.S.","year":"2015","unstructured":"Hoffmann L.S.; Kretschmer A.; Lawrenz B.; Hocher B.; Stasch J-P.; Chronic activation of heme free guanylate cyclase leads to renal protection in dahl salt-sensitive rats. PLoS One 2015,10(12)","journal-title":"PLoS One"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"F1003","DOI":"10.1152\/ajprenal.00229.2014","volume":"307","author":"Dautzenberg M.","year":"2014","unstructured":"Dautzenberg M.; Kahnert A.; Stasch J-P.; Just A.; Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat. Am J Physiol Renal Physiol 2014,307(9),F1003-F1012","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jsxm.2016.12.007","volume":"14","author":"Decaluw\u00e9 K.","year":"2017","unstructured":"Decaluw\u00e9 K.; Pauwels B.; Boydens C.; Thoonen R.; Buys E.S.; Brouckaert P.; Van de Voorde J.; Erectile dysfunction in heme-deficient nitric oxide-unresponsive soluble guanylate cyclase knock-in mice. J Sex Med 2017,14(2),196-204","journal-title":"J Sex Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejps.2016.12.013","volume":"99","author":"Ni R.","year":"2017","unstructured":"Ni R.; Zhao J.; Liu Q.; Liang Z.; Muenster U.; Mao S.; Nanocrystals embedded in chitosan-based respirable swellable microparticles as dry powder for sustained pulmonary drug delivery. Eur J Pharm Sci 2017,99,137-146","journal-title":"Eur J Pharm Sci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1124\/mol.105.018747","volume":"69","author":"Schindler U.","year":"2006","unstructured":"Schindler U.; Strobel H.; Sch\u00f6nafinger K.; Linz W.; L\u00f6hn M.; Martorana P.A.; R\u00fctten H.; Schindler P.W.; Busch A.E.; Sohn M.; T\u00f6pfer A.; Pistorius A.; Jannek C.; M\u00fclsch A.; Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol 2006,69(4),1260-1268","journal-title":"Mol Pharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00395-014-0421-1","volume":"109","author":"Fraccarollo D.","year":"2014","unstructured":"Fraccarollo D.; Galuppo P.; Motschenbacher S.; Ruetten H.; Sch\u00e4fer A.; Bauersachs J.; Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. Basic Res Cardiol 2014,109(4),421","journal-title":"Basic Res Cardiol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1124\/jpet.115.230706","volume":"356","author":"Boustany-Kari C.M.","year":"2016","unstructured":"Boustany-Kari C.M.; Harrison P.C.; Chen H.; Lincoln K.A.; Qian H.S.; Clifford H.; Wang H.; Zhang X.; Gueneva-Boucheva K.; Bosanac T.; Wong D.; Fryer R.M.; Richman J.G.; Sarko C.; Pullen S.S.; A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat. J Pharmacol Exp Ther 2016,356(3),712-719","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1167\/iovs.18-23772","volume":"59","author":"Prasanna G.","year":"2018","unstructured":"Prasanna G.; Ferrara L.; Adams C.; Ehara T.; Li B.; Yang L.; Xiang C.; Ng C.T.H.; Kim S.; Towler C.; Topley T.; McAllister C.; Ghosh M.; Newton R.; Stacy R.; Rice D.S.; Mogi M.; A Novel selective soluble guanylate cyclase activator, MGV354, lowers intraocular pressure in preclinical models, following topical ocular dosing. Invest Ophthalmol Vis Sci 2018,59(5),1704-1716","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1021\/acs.jmedchem.8b00007","volume":"61","author":"Ehara T.","year":"2018","unstructured":"Ehara T.; Adams C.M.; Bevan D.; Ji N.; Meredith E.L.; Belanger D.B.; Powers J.; Kato M.; Solovay C.; Liu D.; Capparelli M.; Bolduc P.; Grob J.E.; Daniels M.H.; Ferrara L.; Yang L.; Li B.; Towler C.S.; Stacy R.C.; Prasanna G.; Mogi M.; The Discovery of (S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1 H-inden-4-yl)pyridin-2-yl)-5-methyl-1 H-pyrazole-4-carboxylic acid, a soluble guanylate cyclase activator specifically designed for topical ocular delivery as a therapy for glaucoma. J Med Chem 2018,61(6),2552-2570","journal-title":"J Med Chem"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/173943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T08:27:26Z","timestamp":1577176046000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/173943\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":94,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,11,29]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557519666190730110600","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}